Immobilized Human CD27, Fc Tag (Cat. No. CD7-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27 Ligand, His,Avitag,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H82D7) with a linear range of 0.1-4 ng/mL (QC tested).
The purity of FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) is more than 85% and the molecular weight of this protein is around 55-74 kDa verified by SEC-MALS.
Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics | Hematologic Neoplasms; Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
iHIVARNA-01 | iHIVARNA-01 | Phase 2 Clinical | Idibaps | HIV Infections | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Allogene Therapeutics Inc | Carcinoma, Renal Cell | Details |
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Hematologic Neoplasms; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous | Details |
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Seattle Genetics Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.